Olmesartan Medoxomil /Amlodipine Sandoz (Olmesartan Medoxomil, Amlodipine)

Olmesartan Medoxil / Amlodipine is an antihypertensive agent that works on the renin‑angiotensin system and calcium‑channel pathways to lower blood pressure.

• Hypertension: provides combined blockade of angiotensin II receptors and calcium‑channel mediated vasoconstriction to achieve better blood‑pressure control.
• Hypertension with high cardiovascular risk: reduces systolic and diastolic pressure, contributing to lower risk of stroke and myocardial infarction.
• Hypertension resistant to monotherapy: offers an additive effect when a single‑agent regimen does not reach target blood pressure.

• Olmesartan medoxil selectively blocks the binding of angiotensin II to the AT‑1 receptor, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combination produces additive blood‑pressure reduction by targeting two complementary pathways involved in vascular tone and fluid balance.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness, especially after the first dose.
• Flushing: transient warmth and redness.
• Fatigue: general feeling of tiredness.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips, tongue or throat.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Hepatic dysfunction: abnormal liver enzymes or hepatitis.
• Renal impairment: worsening kidney function, especially in patients with pre‑existing disease.
• Hyperkalemia: elevated potassium levels, potentially leading to cardiac arrhythmia.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

• Renal function: evaluate creatinine clearance and adjust if necessary.
• Hepatic function: check liver enzymes in patients with known liver disease.
• Electrolytes: monitor potassium levels, particularly when used with potassium‑sparing agents.
• Pregnancy: avoid use during the second and third trimesters; discuss risks if exposure occurs.
• Concomitant antihypertensives: watch for additive blood‑pressure lowering effects.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Olmesartan Medoxil / Amlodipine may interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of hyperkalemia, renal dysfunction.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise amlodipine plasma concentrations.

Moderate Interactions (Monitor Closely)

• Diuretics: additive hypotensive effect, monitor blood pressure and electrolytes.
• NSAIDs: may blunt antihypertensive response and affect renal function.
• Lithium: increased lithium levels, monitor for toxicity.
• Simvastatin: amlodipine can increase simvastatin exposure; consider dose reduction.